Mesa Biotech has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for its Accula SARS-CoV-2 Test, which gives COVID-19 diagnostic results in 30 minutes. Mesa Biotech, a privately-held, molecular diagnostic company has developed the testing platform designed for point-of-care (POC) infectious disease diagnosis. The COVID-19 test uses this patented technology to enable ‘near patient’ testing allowing testing outside of the central laboratory...